| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE1L |
| Uniprot No | P41226 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1012aa |
| 氨基酸序列 | MDALDASKLLDEELYSRQLYVLGSPAMQRIQGARVLVSGLQGLGAEVAKN LVLMGVGSLTLHDPHPTCWSDLAAQFLLSEQDLERSRAEASQELLAQLNR AVQVVVHTGDITEDLLLDFQVVVLTAAKLEEQLKVGTLCHKHGVCFLAAD TRGLVGQLFCDFGEDFTVQDPTEAEPLTAAIQHISQGSPGILTLRKGANT HYFRDGDLVTFSGIEGMVELNDCDPRSIHVREDGSLEIGDTTTFSRYLRG GAITEVKRPKTVRHKSLDTALLQPHVVAQSSQEVHHAHCLHQAFCALHKF QHLHGRPPQPWDPVDAETVVGLARDLEPLKRTEEEPLEEPLDEALVRTVA LSSAGVLSPMVAMLGAVAAQEVLKAISRKFMPLDQWLYFDALDCLPEDGE LLPSPEDCALRGSRYDGQIAVFGAGFQEKLRRQHYLLVGAGAIGCELLKV FALVGLGAGNSGGLTVVDMDHIERSNLSRQFLFRSQDVGRPKAEVAAAAA RGLNPDLQVIPLTYPLDPTTEHIYGDNFFSRVDGVAAALDSFQARRYVAA RCTHYLKPLLEAGTSGTWGSATVFMPHVTEAYRAPASAAASEDAPYPVCT VRYFPSTAEHTLQWARHEFEELFRLSAETINHHQQAHTSLADMDEPQTLT LLKPVLGVLRVRPQNWQDCVAWALGHWKLCFHYGIKQLLRHFPPNKVLED GTPFWSGPKQCPQPLEFDTNQDTHLLYVLAAANLYAQMHGLPGSQDWTAL RELLKLLPQPDPQQMAPIFASNLELASASAEFGPEQQKELNKALEVWSVG PPLKPLMFEKDDDSNFHVDFVVAAASLRCQNYGIPPVNRAQSKRIVGQII PAIATTTAAVAGLLGLELYKVVSGPRPRSAFRHSYLHLAENYLIRYMPFA PAIQTFHHLKWTSWDRLKVPAGQPERTLESLLAHLQEQHGLRVRILLHGS ALLYAAGWSPEKQAQHLPLRVTELVQQLTGQAPAPGQRVLVLELSCEGDD EDTAFPPLHYEL |
| 预测分子量 | 138 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBE1L重组蛋白的3篇参考文献及其摘要概括：
---
1. **"UBE1L is required for ISG15 conjugation during influenza A virus infection"**
*Authors: Zhao C., Denison C., Huibregtse J.M., et al.*
**摘要**：本研究探讨了UBE1L在流感病毒感染过程中对ISG15共轭化的作用。通过重组UBE1L蛋白的体外实验，发现其作为ISG15激活酶(E1酶)对ISGylation(ISG15与靶蛋白的结合)至关重要，并证实其在抗病毒反应中的关键功能。
2. **"UBE1L interacts with the retinoic acid receptor α and enhances its degradation in lung cancer cells"**
*Authors: Kitareewan S., Pitha-Rowe I., Ma D., et al.*
**摘要**：该研究利用重组UBE1L蛋白分析了其与视黄酸受体α(RARα)的相互作用机制。结果表明，UBE1L通过泛素-蛋白酶体系统促进RARα的降解，揭示了UBE1L在肺癌细胞中的肿瘤抑制潜力。
3. **"Recombinant UBE1L catalyzes ISG15 activation in vitro: Insights into the enzymatic mechanism of ubiquitin-like modifiers"**
*Authors: Jeon Y.J., Yoo H.M., Chung C.H.*
**摘要**：文章报道了重组UBE1L蛋白在大肠杆菌中的表达与纯化，并通过体外酶活实验验证了其催化ISG15与靶蛋白结合的活性。研究进一步解析了UBE1L在泛素样修饰通路中的特异性机制。
---
**备注**：若需更多文献，可扩展检索关键词(如UBE1L重组蛋白功能、结构解析或疾病模型应用)，或结合具体研究领域补充。
UBE1L (Ubiquitin-Activating Enzyme E1-Like), also known as UBA7. is a member of the E1 enzyme family that initiates the ubiquitin-proteasome system (UPS), a critical pathway for protein degradation and cellular regulation. Unlike its homolog UBE1 (responsible for activating ubiquitin), UBE1L specifically activates ISG15 (Interferon-Stimulated Gene 15), a ubiquitin-like protein induced during immune responses. This unique function links UBE1L to antiviral defense, inflammation, and cancer biology.
Recombinant UBE1L protein is engineered using expression systems like *E. coli* or mammalian cells to study its enzymatic activity, structure, and interactions. Its production enables researchers to dissect the ISGylation pathway—a post-translational modification analogous to ubiquitination—where ISG15 conjugates to target proteins to modulate their stability, localization, or function. Dysregulation of UBE1L has been implicated in diseases such as lung cancer, viral infections (e.g., influenza, HIV), and autoimmune disorders, highlighting its therapeutic potential.
Studies using recombinant UBE1L have clarified its role in interferon signaling, particularly in enhancing antiviral responses by promoting ISG15-mediated inhibition of viral replication. Structural analyses reveal conserved ATP-binding domains critical for its enzymatic activity. Additionally, UBE1L is explored as a biomarker or drug target, with inhibitors under investigation for cancer treatment. Its recombinant form serves as a tool for high-throughput screening and mechanistic studies, bridging molecular insights to clinical applications in precision medicine.
×
